Outcomes of very high‐risk prostate cancer after radical prostatectomy: Validation study from 3 centers

Sundi, Debasish; Tosoian, Jeffrey J.; Nyame, Yaw A.; Alam, Ridwan; Achim, Mary; Reichard, Chad A.; Li, Jianbo; Wilkins, Lamont; Schwen, Zeyad; Han, Misop; Davis, John W.; Klein, Eric A.; Schaeffer, Edward M.; Stephenson, Andrew J.; Ross, Ashley E.; Chapin, Brian F.

doi:10.1002/cncr.31833

Cited by 43 publications

(33 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As we know, there were few studies evaluating the prognosis differences between RP and EBRT in aging 75 and older patients with VHR PCa. Sundi et al [21] analyzed the outcomes of HR PCa and VHR PCa after the treatment of RP, and found that the 5-year all-cause mortality and cancer-specific mortality were 0.033 and 0.007 in patients with HR PCa and 0.006 and 0.045 in those with VHR PCa. Reichard et al [22] reported that the all-cause mortality rate of RP and radiotherapy for patients with HR PCa and VHR PCa were 9.5% and 8.2%.…”

Section: Discussionmentioning

confidence: 99%

Superior survival benefits of Radical Prostatectomy than External Beam Radiotherapy in aging 75 and older men with high-risk or very high-risk Prostate Cancer: a population-matched study

et al. 2020

View full text Add to dashboard Cite

Objective: To evaluate the survival difference of radical prostatectomy (RP) and external beam radiotherapy (EBRT) in elderly men (75 years and older) with high-risk (HR) or very high-risk (VHR) prostate cancer (PCa). Methods: Elderly men diagnosed with HR/VHR PCa from 2004-2015 in the Surveillance, Epidemiology and End Results (SEER) database were identified. Propensity-score matching (PSM) was conducted to balance the covariates; Kaplan-Meier and Cox analysis were performed to evaluate the overall survival (OS) and prostate cancer-specific survival (PCSS). Results: 11698 patients with HR PCa and 4415 patients with VHR PCa were identified and divided into RP and EBRT group. After PSM, 964 patients with HR PCa and 538 patients with VHR PCa were included in each group. The 10-year OS and PCSS of men with HR PCa were 60.1% vs 40.9% and 90.6% vs 83.4%, respectively. The 10-year rate of OS and PCSS in men with VHR PCa were 55.9% vs 33.3% and 82.4% vs 75.6%, respectively. The OS curve of patients with HR PCa revealed that RP was significantly better than EBRT in both overall cohort [HR: 0.533, 95%CI (0.485~0.586), p<0.001] and the matched cohort [HR: 0.703, 95%CI (0.595~0.832), p<0.001]. However, the PCSS curve of patients with HR PCa showed that RP was significantly better than EBRT in overall cohort [HR: 0.453, 95%CI (0.368~0.559), p<0.001] but was similar to EBRT in matched cohort [HR: 0.820, 95%CI (0.552~1.218), p=0.327]. As for patients with VHR PCa, RP was associated with better OS than EBRT whether in overall cohort [HR: 0.520, 95%CI (0.457~0.592), p<0.001] or matched cohort [0.695, 95%CI (0.551~0.876), p=0.002]. The PCSS of RP was significantly better than that of EBRT in overall cohort [HR: 0.538, 95%CI (0.422~ 0.685), p<0.001], but was similar in matched cohort [HR: 0.787, 95%CI (0.510 ~1.214), p=0.281]. Conclusions: RP has more survival benefits than EBRT in men aged 75 years and older with HR or VHR PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Superior survival benefits of Radical Prostatectomy than External Beam Radiotherapy in aging 75 and older men with high-risk or very high-risk Prostate Cancer: a population-matched study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We reviewed a pooled meta‐data set of 1776 patients with high‐risk or VHR prostate cancer who underwent RP across three centres. Detailed overall cohort characteristics have been described previously . In all, 1392 patients from three tertiary centres who underwent RP for either high‐risk or VHR disease, from 2005 to 2015, were included in the present analysis, after excluding patients who received neoadjuvant ADT or underwent RP at >1 year from diagnosis.…”

Section: Methodsmentioning

confidence: 99%

Does time from diagnosis to treatment of high‐ or very‐high‐risk prostate cancer affect outcome?

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objective To determine whether time from diagnosis to treatment impacted outcomes in a multicentre cohort of high‐ and very‐high‐risk (VHR) patients with prostate cancer undergoing radical prostatectomy (RP). Patients and Methods In all, 1392 patients from three tertiary centres who underwent RP for either high‐risk or VHR disease, from 2005 to 2015, were identified. The cohort was divided into tertiles based on time from diagnostic biopsy to RP. Cumulative incidence of biochemical recurrence (BCR), metastasis, and prostate cancer‐specific mortality (PCSM) were calculated for each tertile. The Kaplan–Meier method was used to evaluate for differences in all‐cause mortality (ACM) amongst tertiles. Competing risks regression models, as well as Cox proportional hazards regression models, were fitted to assess the association between time‐to‐event outcomes and patient characteristics. Results The median (interquartile range [IQR]) time from biopsy to RP was 68 (50–94) days. The median (IQR) follow‐up was 31 (12.1–55.7) months. The cumulative incidence of BCR (P = 0.14), metastasis (P = 0.15), and PCSM (P = 0.69) did not differ amongst time‐to‐treatment tertiles of VHR patients. Also, Kaplan–Meier estimates of ACM (P = 0.53) did not differ amongst time‐to‐treatment tertiles. Similarly, BCR, metastasis, PCSM, and ACM did not significantly differ amongst time‐to‐treatment tertiles in multivariable modelling. Conclusion In this pooled meta‐dataset of patients with high‐risk or VHR prostate cancer, time from diagnosis to RP did not appear to significantly contribute to differences in clinical outcomes. This finding supports the safety of enrollment of such patients into neoadjuvant clinical trials.

show abstract

“…Increased in lung cancer patients. [ 44,46,23,47,35,98] Heat-shock proteins Stress response. Overexpression in several types of tumor.…”

Section: Annexinmentioning

confidence: 99%

Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

Gasparri

Sedda

Noberini

et al. 2020

Proteomics Clinical Apps

View full text Add to dashboard Cite

The current knowledge on proteomic biomarker analysis for the early diagnosis of lung cancer is summarized, underlining the diversity among the results and the current interest in translating research results into clinical practice. A MEDLINE/PubMed literature search to retrieve all the papers published in the last 10 years is performed. Proteomics studies on lung cancer have gathered evidence on the potential role of biomarkers in early diagnosis. Although promising, none of them have proved to be sufficiently reliable to achieve validation. Future research should evolve toward a multipanel analysis of proteins, considering the possibility that individual biomarkers might not be specific enough to diagnose lung cancer, but could be related to oncological conditions.

show abstract

Outcomes of very high‐risk prostate cancer after radical prostatectomy: Validation study from 3 centers

Cited by 43 publications

References 25 publications

Superior survival benefits of Radical Prostatectomy than External Beam Radiotherapy in aging 75 and older men with high-risk or very high-risk Prostate Cancer: a population-matched study

Superior survival benefits of Radical Prostatectomy than External Beam Radiotherapy in aging 75 and older men with high-risk or very high-risk Prostate Cancer: a population-matched study

Does time from diagnosis to treatment of high‐ or very‐high‐risk prostate cancer affect outcome?

Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

Contact Info

Product

Resources

About